Is BioCryst Pharmaceuticals Stock a Good Investment?
BioCryst Pharmaceuticals Investment Advice | BCRX |
- Examine BioCryst Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BioCryst Pharmaceuticals' leadership team and their track record. Good management can help BioCryst Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact BioCryst Pharmaceuticals' business and its evolving consumer preferences.
- Compare BioCryst Pharmaceuticals' performance and market position to its competitors. Analyze how BioCryst Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if BioCryst Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BioCryst Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in BioCryst Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if BioCryst Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine BioCryst Pharmaceuticals Stock
Researching BioCryst Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 86.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.61. BioCryst Pharmaceuticals had not issued any dividends in recent years.
To determine if BioCryst Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioCryst Pharmaceuticals' research are outlined below:
| BioCryst Pharmaceuticals generated a negative expected return over the last 90 days | |
| BioCryst Pharmaceuticals has high historical volatility and very poor performance | |
| BioCryst Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 331.41 M. Net Loss for the year was (226.54 M) with profit before overhead, payroll, taxes, and interest of 10.94 M. | |
| BioCryst Pharmaceuticals currently holds about 417.48 M in cash with (95.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.24. | |
| BioCryst Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: BNP Paribas Financial Markets Has 3.78 Million Stake in BioCryst Pharmaceuticals, Inc. - MarketBeat |
BioCryst Pharmaceuticals Quarterly Cash And Short Term Investments |
|
BioCryst Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioCryst Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioCryst Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact BioCryst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises BioCryst Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2017-08-07 | 2017-06-30 | -0.19 | -0.21 | -0.02 | 10 | ||
2013-02-19 | 2012-12-31 | -0.16 | -0.18 | -0.02 | 12 | ||
2004-02-04 | 2003-12-31 | -0.2 | -0.18 | 0.02 | 10 | ||
2000-10-25 | 2000-09-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2000-02-02 | 1999-12-31 | -0.01 | -0.03 | -0.02 | 200 | ||
2013-11-05 | 2013-09-30 | -0.11 | -0.14 | -0.03 | 27 | ||
2007-05-09 | 2007-03-31 | -0.27 | -0.3 | -0.03 | 11 |
Know BioCryst Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioCryst Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioCryst Pharmaceuticals backward and forwards among themselves. BioCryst Pharmaceuticals' institutional investor refers to the entity that pools money to purchase BioCryst Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fisher Asset Management, Llc | 2024-09-30 | 3.3 M | Gw&k Investment Management, Llc | 2024-09-30 | 3.3 M | Caligan Partners Lp | 2024-09-30 | 2.6 M | Goldman Sachs Group Inc | 2024-09-30 | 2.3 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 2.3 M | Two Sigma Advisers, Llc | 2024-09-30 | 2.2 M | Rice Hall James & Associates, Llc | 2024-09-30 | 2.2 M | Fmr Inc | 2024-09-30 | 2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 20.3 M | Blackrock Inc | 2024-06-30 | 20 M |
BioCryst Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.56 B.Market Cap |
|
BioCryst Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | 0.50 | 0.52 |
Determining BioCryst Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if BioCryst Pharmaceuticals is a good buy. For example, gross profit margin measures BioCryst Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioCryst Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioCryst Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioCryst Pharmaceuticals. Check BioCryst Pharmaceuticals' Beneish M Score to see the likelihood of BioCryst Pharmaceuticals' management manipulating its earnings.
Evaluate BioCryst Pharmaceuticals' management efficiency
BioCryst Pharmaceuticals has return on total asset (ROA) of (0.0425) % which means that it has lost $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.52 in 2024, whereas Return On Tangible Assets are likely to drop (0.46) in 2024. At this time, BioCryst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 24.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 76 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.37) | (2.25) | |
| Tangible Book Value Per Share | (2.37) | (2.25) | |
| Enterprise Value Over EBITDA | (16.24) | (17.05) | |
| Price Book Value Ratio | (2.53) | (2.40) | |
| Enterprise Value Multiple | (16.24) | (17.05) | |
| Price Fair Value | (2.53) | (2.40) | |
| Enterprise Value | 112.6 M | 115.2 M |
The strategic initiatives led by BioCryst Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.887 |
Basic technical analysis of BioCryst Stock
As of the 16th of December 2024, BioCryst Pharmaceuticals shows the Downside Deviation of 3.63, risk adjusted performance of 0.0099, and Mean Deviation of 2.33. BioCryst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioCryst Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioCryst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioCryst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioCryst Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioCryst Pharmaceuticals' Outstanding Corporate Bonds
BioCryst Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioCryst Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioCryst bonds can be classified according to their maturity, which is the date when BioCryst Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIO 33 15 MAR 27 Corp BondUS090572AR99 | View | |
| BIO 37 15 MAR 32 Corp BondUS090572AQ17 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand BioCryst Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioCryst Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0099 | |||
| Market Risk Adjusted Performance | 0.0099 | |||
| Mean Deviation | 2.33 | |||
| Semi Deviation | 3.45 | |||
| Downside Deviation | 3.63 | |||
| Coefficient Of Variation | 33757.32 | |||
| Standard Deviation | 3.27 | |||
| Variance | 10.7 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0.0001) | |||
| Maximum Drawdown | 18.53 | |||
| Value At Risk | (4.34) | |||
| Potential Upside | 5.27 | |||
| Downside Variance | 13.19 | |||
| Semi Variance | 11.9 | |||
| Expected Short fall | (2.27) | |||
| Skewness | (0.44) | |||
| Kurtosis | 3.35 |
| Risk Adjusted Performance | 0.0099 | |||
| Market Risk Adjusted Performance | 0.0099 | |||
| Mean Deviation | 2.33 | |||
| Semi Deviation | 3.45 | |||
| Downside Deviation | 3.63 | |||
| Coefficient Of Variation | 33757.32 | |||
| Standard Deviation | 3.27 | |||
| Variance | 10.7 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0.0001) | |||
| Maximum Drawdown | 18.53 | |||
| Value At Risk | (4.34) | |||
| Potential Upside | 5.27 | |||
| Downside Variance | 13.19 | |||
| Semi Variance | 11.9 | |||
| Expected Short fall | (2.27) | |||
| Skewness | (0.44) | |||
| Kurtosis | 3.35 |
Consider BioCryst Pharmaceuticals' intraday indicators
BioCryst Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioCryst Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0367 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 7.49 | |||
| Day Typical Price | 7.44 | |||
| Market Facilitation Index | 0.28 | |||
| Price Action Indicator | (0.14) |
BioCryst Pharmaceuticals Corporate Filings
F4 | 2nd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 7th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
BioCryst Stock media impact
Far too much social signal, news, headlines, and media speculation about BioCryst Pharmaceuticals that are available to investors today. That information is available publicly through BioCryst media outlets and privately through word of mouth or via BioCryst internal channels. However, regardless of the origin, that massive amount of BioCryst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioCryst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioCryst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioCryst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioCryst Pharmaceuticals alpha.
BioCryst Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioCryst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioCryst Pharmaceuticals Corporate Management
| Yarlagadda Babu | Sr. VP of Drug Discovery | Profile | |
| Alane Barnes | VP, General Counsel and Corporate Secretary | Profile | |
| Elliott Berger | VP Affairs | Profile | |
| William MBBS | Chief Officer | Profile | |
| Stephanie Angelini | Chief Officer | Profile | |
| Michael Jones | Executive Officer | Profile | |
| Clayton Fletcher | Chief Officer | Profile |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.